Nonalcoholic steatohepatitis (NASH) is an increasingly common cause of chronic liver disease worldwide. Currently, no specific pharmacologic therapy has been shown to treat NASH effectively. Because ...

Please provide your email address to receive an email when new articles are posted on . Both 15 mg and 30 mg pioglitazone doses have similar efficacy as 45 mg for preventing new-onset diabetes, stroke ...

Amsterdam, The Netherlands, Sept. 19, 2007 -- New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), further ...

The second study, by Dr Yaping Xu (Takeda Pharmaceuticals) and colleagues, was a retrospective analysis of the US healthcare plan database i3 Innovus. Xu et al report that risk of stroke and MI were ...

New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), further support the cardiovascular safety of ACTOS(R) ...